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AbstrACt
Objective To assess whether the use of multiple 
antidiabetic medications is associated with an increased 
risk of hypoglycaemia in patients with type 2 diabetes 
mellitus.
Design A case-crossover study.
setting Cases were enrolled from the National Center for 
Diabetes, Endocrinology and Genetics in Amman, Jordan.
Participants Patients were those with diabetes mellitus 
and reported incident of a hypoglycaemic event in their 
medical records during the period January 2007 to July 
2017. Patients with multiple antidiabetic medications were 
those with at least two antidiabetic medications.
Primary outcome History of antidiabetic medication use 
was extracted from the pharmacy records. The use of 
multiple antidiabetic medications during the risk window 
(before hypoglycaemia) was compared with a control 
window(s) (earlier time) of the same length after a washout 
period. Conditional logistic regression was applied to 
evaluate the OR of hypoglycaemia between the treatment 
groups. A secondary analysis was performed in patients 
with a blood glucose measurement of ≤70 mg/dL.
results 182 patients (106 females, 58.2%) were 
included in the study with an average age of 59.9 years 
(SD=9.9). The patients’ average body mass index was 
31.7 kg/m2 (SD=6.2). Compared with monotherapy, the 
OR of hypoglycaemic events for patients with multiple 
antidiabetic medications was 5.00 (95% CI 1.10 to 22.82). 
The OR was 6.00 (95% CI 0.72 to 49.84) for the secondary 
analysis patient group (n=94). Ten-fold increased risk was 
found in patients (n=155) with insulin and sulfonylurea-
based combination therapy (OR 10.00;95% CI 1.28 to 
78.12).
Conclusion This study shows that the use of multiple 
antidiabetic medications appears to increase the risk 
of hypoglycaemic events. Patients and healthcare 
professionals should be extra vigilant when patients are on 
multiple antidiabetic medications therapy, especially the 
combination of sulfonylurea and insulin.
IntrODuCtIOn 
Diabetes mellitus (DM) is a progressive 
disease and patients need to be treated effi-
ciently to prevent the development of its 
complications.1 Comprehensive manage-
ment for patients with uncontrolled diabetes 
includes an appropriate dietary plan, exer-
cise and antidiabetic medication therapy. 
However, antidiabetic monotherapy does 
not always achieve the optimal blood glucose 
control,2 and patients may need intensive 
antidiabetic therapy in order to reduce 
the blood glucose level to a normal range.3 
Treatment intensification can be done either 
through increasing the dose of a single anti-
diabetic agent, or by administration of combi-
nation therapy using multiple antidiabetic 
medications.4 
Previous studies across different countries 
have shown that the prevalence rate of hypo-
glycaemic events has increased during the 
past decade,5–7 highlighting that there is a 
continuous problem among patients with 
DM and their current antidiabetic treatment. 
A recent ecological study observed increases 
in both the prescribing of multiple antidia-
betic medications and the rate of hospitalised 
hypoglycaemic events in the UK.7 However, 
the results do not necessarily infer that use 
of multiple antidiabetic medications therapy 
strengths and limitations of this study
 ► This study provides evidence for a better under-
standing of the association between the use of mul-
tiple antidiabetic medications and hypoglycaemia.
 ► This is the first study to investigate this association 
in the Middle East and to extend the generalisabil-
ity of the current evidence beyond the Caucasian 
population.
 ► The use of case-crossover as a self-matching study 
design minimised the effect of time-independent 
confounders.
 ► The small sample size of our study cohort led to 
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was associated with the increase in hypoglycaemic events. 
Previous studies have only assessed the effectiveness and 
safety of individual drug or combination therapies in 
relation to hypoglycaemic outcomes. Therefore, there is 
a lack of evidence on the effect of the number of antidia-
betic drug used on the risk of hypoglycaemic events. This 
study aimed to determine whether the risk of hypogly-
caemic events is increased by exposure to multiple anti-
diabetic medications.
MethODs
Data source and extraction
This study was conducted using patients’ medical records 
from the National Center for Diabetes, Endocrinology 
and Genetics (NCDEG) registry.8 The NCDEG is an inde-
pendent non-profit healthcare organisation in Amman, 
Jordan. It was established in 1996 to provide healthcare 
of high quality, education and training in the fields of 
diabetes, endocrinology and genetic diseases to more 
than 25 000 patients. This centre provides healthcare 
services to patients under governmental and private 
health insurance and for private patients who are willing 
to self-fund their healthcare. It is designated as a WHO 
collaborating centre for diabetes research, education and 
primary health care.8 Healthcare services are provided 
to patients with diabetes through a multidisciplinary 
team of specialised endocrinologists, specialised nurses, 
diabetic educators, clinical nutritionists and podiatrists.8 
The scientific and technical standards of data processing 
and healthcare services provision in the centre meet 
WHO standards.9 Hypoglycaemic events were identified 
through a manual search of patients’ medical records, 
and antidiabetic medications dispensing data were 
extracted from the pharmacy records. Patients reported 
the hypoglycaemic events data, and they were confirmed 
and documented in the medical records by the treating 
physician.
study design
A case-crossover study10 was conducted to evaluate the 
association between the use of multiple antidiabetic 
medications therapy and the risk of hypoglycaemia 
among patients with DM. The case-crossover design is a 
variant of case–control study design.11 It has the advan-
tage of minimising the effect of measured and unmea-
sured confounding variables, and does not require a 
large number of patients because the cases themselves 
act as the control in this type of study design.11 12 Only 
individuals with hypoglycaemic events were included in 
the study. Therefore, time-invariant confounding factors 
such as patients’ characteristics (sex and family history), 
smoking status, type of diabetes, presence of comorbid 
diseases or any unmeasured confounders constant over 
time were eliminated. The case-crossover design minimise 
bias that may be caused by selective selection of controls, 
which is a common problem in case–control studies.10 
The case-crossover design has been used previously to 
study adverse drug reactions.13–15 The case-crossover 
design compares the exposure of interest which is expo-
sure odds of multiple antidiabetic medications therapy 
during a defined case window (or risk window) with the 
odds in the preceding control window(s) within the same 
patients as shown in figure 1.
study outcome and case definition
The outcome was defined as all hypoglycaemic events 
between January 2007 and July 2017. Cases were identified 
as all patients who met the following inclusion criteria:
1. With type 2 DM.
2. A hypoglycaemic event during the study period.
3. At least 12 months medical records history before the 
date of hypoglycaemia event (index date).
risk and control window definition
The case window (or the risk window) is the period 
before the recorded hypoglycaemic event (index date). 
The control window is the period that precedes this 
case window. Between the case window and the control 
window, a washout period was included to minimise the 
possibility of any carryover effect from the control period 
to the risk period.16 A 15-day window was selected for the 
primary analysis. The risk window of 30 days was used 
for the sensitivity analysis to test the robustness of the 
findings of the primary analysis. For the primary anal-
ysis, the exposure to multiple antidiabetic medications 
therapy in the 15 days (days 1–15 before the index date) 
that preceded the event (the risk window) was compared 
with a preceding control period of the same length (days 
46–60 before the index date), with a washout period of 30 
days (days 16–45 before the index date) between the risk 
window and the control window, refer to figure 1.
exposure definition
The use of multiple antidiabetic medications therapy was 
defined as the concurrent use of two or more antidiabetic 
Figure 1 Risk and control windows in the study design.
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medications. The full medications use history was 
retrieved from the pharmacy records for each patient.
Data quality control
The data were extracted manually from the medical 
records of the patients by the researcher (AYN) using a 
predesigned data extraction form. The accuracy and the 
quality of the data entry and extraction were checked by 
another pharmacist from random sample of 20 records. 
The accuracy of the extracted data was 100%.
Patient and public involvement
Patients were not involved in any aspect of the design or 
conduct of this study.
statistical analysis
Descriptive statistics were used to describe patients’ 
demographic characteristics, medications use and comor-
bidities. Continuous data were reported as mean±SD, and 
categorical data were reported as percentages (frequen-
cies). Conditional logistic regression was used to estimate 
the OR for comparing the use of multiple antidiabetic 
medications therapy during the risk window with the 
control window, compared with that for antidiabetic 
monotherapy. A two-sided p<0.05 was considered as statis-
tically significant.
secondary and sensitivity analyses
Secondary analysis was performed to calculate the OR 
for patients with confirmed hypoglycaemic events and 
blood glucose measurement (≤70 mg/dL) as recom-
mended by the American Diabetes Association.17 Sensi-
tivity analyses were conducted: using 30 days risk window 
(model number 1), using 7 days washout period (model 
number 2) and using multiple (four) control windows 
(model number 3). In addition, the same analyses were 
performed for patients taking multiple antidiabetic 
therapies based on insulin or sulfonylurea. These sensi-
tivity analyses used different inclusion criteria for study 
cases, with confirmed hypoglycaemia with blood glucose 
measurement (≤70 mg/dL), shorter washout period to 
assess the internal validity of the drug use,18 and multiple 
control windows to increase the statistical power of 
estimates as recommended in the literature,19 thereby 
increased the reliability of the OR calculations. All the 
analyses were conducted using Stata (V.15).
results
Cohort size and patient characteristics
Of 470 patient records were reviewed, 183 patients with 
an incident of hypoglycaemia and met the inclusion 
criteria were identified. One patient was diagnosed with 
prediabetes, and thus was excluded from the study. For 
secondary analysis, cases were restricted to patients who 
had blood glucose measurements of ≤70 mg/dL (n=94 
patients), as shown in figure 2.
Patient characteristics
Of the 182 patients, 58.2% (n=106) were females. The 
average age was 59.9 years old (SD=9.9). The average 
body mass index (BMI) of the patients was 31.7 kg/m2 
(SD=6.2). The majority of patients were married (n=158, 
86.8%) and 30 (16.5%) reported a family history of DM. 
While 26.4% (n=48) of patients were either smokers or 
ex-smokers, none of the patients reported any current 
or previous alcohol consumption. Demographics charac-
teristics of patients in the primary study cohort and the 
secondary subcohort was comparable and is shown in 
table 1.
The majority of the patients (n=167, 91.8%) were diag-
nosed with, and receiving treatment for more than one 
chronic condition. The two most common chronic condi-
tions in the study sample were hypertension and dyslip-
idaemia, which affected around 86.3% and 76.9% of 
the patients, respectively. In addition to this, microalbu-
minuria was also prevalent (42.3%) among the patients 
(table 2).
treatment characteristics
The majority of patients were receiving oral antidia-
betic medications only (as monotherapy or combination 
therapy) at the time when the hypoglycaemia was expe-
rienced (n=90, 49.5%). Other patients were using oral 
antidiabetic medications and insulin injection combina-
tion as antidiabetic therapy (n=82, 45.1%), at the time 
of this event, followed by insulin injection use only (n=8, 
4.4%), and other injectable antidiabetic medications 
and insulin combination (n=1, 0.5%). In addition, one 
patient (0.5%) was managed on diet and exercise only.
The most commonly used antidiabetic therapy was 
combination therapy of metformin and sulfonylurea, 
used by 60 (33.0%) patients followed by metformin and 
insulin combination therapy (n=55, 30.2%). Patients 
managed using combination therapies based on sulfo-
nylurea or insulin medications (n=155, 85.2%) were the 
most prevalent compared with other combination thera-
pies. Antidiabetic dual therapy was used by 120 (65.9%) 
patients with 38 patients (20.9%) prescribed antidiabetic 
triple therapy and one patient (0.5%) using of quadruple 
therapy. Only 12.1% of the patients (n=22) were using 
antidiabetic monotherapy.
The use of cardiovascular system medications was 
noticeable and prevalent across the patients with aspirin 
(n=128, 70.3%) and statins (n=131, 72.0%) the most 
commonly chronic medications prescribed.
risk of hypoglycaemic event
Table 3 shows the results of the primary, secondary and 
sensitivity analyses for the risk of hypoglycaemia due to 
the use of multiple antidiabetic medications therapy.
risk of hypoglycaemia for the primary study cohort
Regardless of the length of risk windows (15 days and 
30 days), the use of single or multiple control windows, 
and the length of washout periods (7 days and 30 days), 
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all primary and sensitivity analyses confirmed an increase 
in the risk of hypoglycaemia among users of multiple anti-
diabetic medications (table 3). However, some of these 
were not statistically significant. Compared with antidi-
abetic monotherapy, the OR of hypoglycaemic events 
for patients with DM exposed to multiple antidiabetic 
medications therapy was 5.00 (95% CI 1.10 to 22.82) for 
the primary analysis (table 3). Sensitivity analyses using 
30 days risk window, 7 days washout period and multiple 
control windows confirmed the primary analysis findings. 
However, some of these were statistically non-significant. 
In addition, another sensitivity analysis was conducted 
using a different definition for exposure (use of three 
or more antidiabetic medications), which showed the 
same risk direction with non-significant results due to 
small sample size (n=38) (results are not included in this 
manuscript).
risk of hypoglycaemia for patients with glucose measurement 
below 70 mg/dl
Similar to the primary analysis, an increase in the risk 
of hypoglycaemia among the users of multiple antidia-
betic medications therapy was observed using different 
risk windows, different washout period and multiple 
control windows, but the effects did not reach statistical 
significance in some of these, (see table 3). Compared 
with antidiabetic monotherapy, the OR of hypogly-
caemic events for patients exposed to multiple antidi-
abetic medications therapy was 6.00 (95% CI 0.72 to 
49.84). Restriction of the study sample in the secondary 
subcohort analyses, to patients who had a blood glucose 
measurement of ≤70 mg/dL, resulted in statistically 
non-significant results due to the small sample size 
(n=94 patients).
risk of hypoglycaemia for patients on insulin or sulfonylurea-
based combination therapies
Insulin and sulfonylurea-based combination therapies 
were the most common therapies in the study cohort 
(n=155, 85.2%). Compared with antidiabetic mono-
therapy, the OR of hypoglycaemic events for patients with 
DM who were exposed to multiple antidiabetic medica-
tions therapy based on sulfonylurea or insulin was 10.00 
(95% CI 1.28 to 78.12), which is a larger change in odds 
compared with the odds of being exposed to any antidi-
abetic combination therapy. Table 4 shows the results of 
the case-crossover analyses for the risk of hypoglycaemia 
due to the use of multiple antidiabetic medications 
therapy based on sulfonylurea or insulin.
Figure 2 Flow chart of the patients included in the case-crossover study.
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DIsCussIOn
This study found that the use of multiple antidiabetic 
medications therapy was significantly associated with 
an increased odds of hypoglycaemia, when compared 
with antidiabetic monotherapy. In addition, the use of 
antidiabetic combination therapies based on insulin or 
sulfonylurea showed a higher odds of hypoglycaemic 
events when compared with the use of any other antidia-
betic combination therapy.
This study explored the effect of the use of multiple 
antidiabetic medications in general (any antidiabetic 
combination therapy) without restricting comparison to 
a specific antidiabetic agent or therapeutic classification. 
The use of multiple antidiabetic medications therapy 
was found to be associated with a fivefold increased odd 
of hypoglycaemia. These results were confirmed using 
two case definitions, the first included all patients with 
reported hypoglycaemic events, and the second was 
restricted to patients who had blood glucose measure-
ments of ≤70 mg/dL.
the use of multiple antidiabetic medications and 
hypoglycaemic events
The findings of this study support a recent ecological study 
conducted in the UK,7 which showed similar increasing 
trends between the use of multiple antidiabetic medica-
tions therapy and the risk of hypoglycaemia. Similar to 
our study findings, a previous database study by Hippis-
ley-Cox and Coupland in the UK reported that the use of 
different antidiabetic combination therapies compared 
with metformin monotherapy was associated with a higher 
risk of hospitalisation for hypoglycaemia.20 However, the 
findings of their study were restricted to patients who 
have been hospitalised for hypoglycaemia, therefore only 
Table 1 Baseline characteristics of patients reported 
hypoglycaemia (n=182), and for the subcohort (n=94) used 











Age (years±SD) 59.9±9.9 59.2±10.1
Gender
  Male 76 (41.8) 37 (39.4)
  Female 106 (58.2) 57 (60.6)
Marital status
  Married 158 (86.6) 80 (85.1)
  Divorced 20 (11.0) 11 (11.7)
  Single 4 (2.2) 3 (3.2)
Smoking status
  Non-smoker 134 (73.6) 70 (74.5)
  Ex-smoker 18 (9.9) 7 (7.4)
  Smoker 30 (16.5) 17 (18.1)
BMI
  Mean BMI±SD 31.7±6.2 31.4±5.8
Duration of diabetes 
mellitus (years±SD)
11.3±7.2† 11.5±7.2
Family history of 
diabetes
30 (16.5) 17 (18.1)
Employment status
  Employed 49 (27.2)‡ 24 (25.5)
  Unemployed or retired 131 (72.8) 70 (74.5)
Monthly income 
(JOD)*, median (IQR)
400 (220) 380 (220)
Insured patients 178 (97.8) 93 (98.9)
Patients on proper diet 106 (58.2) 65 (69.1)
Patients performing 
30 min exercise daily
9 (5.4)§ 6 (6.9)** 
Patients compliant with 
therapy
174 (95.6) 89 (94.7)
Glucose level at the time 
of the event (mg/dL)
60.5±14.7¶ 55.6±14.7







BMI, body mass index; JOD, Jordanian dinar.
Table 2 Prevalence of chronic diseases in the study 
sample
Chronic disease No (%), n=182
Cardiovascular diseases 36 (19.8)
Stroke 4 (2.2)
Retinopathy 3 (1.6)









Thyroid problems 17 (9.3)
Sleep apnoea 1 (0.5)






















pen: first published as 10.1136/bm






6 Naser AY, et al. BMJ Open 2018;8:e024909. doi:10.1136/bmjopen-2018-024909
Open access 
included severe hypoglycaemic events. In Hippisley-Cox’s 
study,20 the OR of hypoglycaemic event comparing the 
use of metformin monotherapy to different antidiabetic 
combination therapies ranged from 1.23 (95% CI 0.84 
to 1.80) to 23.91 (95% CI 19.89 to 28.75) for the users 
of sulfonylurea and insulin combination therapy. When 
compared with the use of three or more antidiabetic 
medications it ranged from 4.31 (95% CI 3.26 to 5.68) to 
13.17 (95% CI 1.14 to 15.57), which were similar to our 
findings of an increased odds of hypoglycaemia among 
users of multiple antidiabetic medications.
We found that the OR for hypoglycaemia was higher 
among users of two or more antidiabetic medications 
compared with that among users of three or more anti-
diabetic medications, which confirmed the results of 
a previous study.20 Nevertheless, this could not be fully 
confirmed since the majority of sensitivity analyses that 
used the other definition for exposure (the use of three 
or more antidiabetic medications), did not reach signifi-
cance level (results are not included in this manuscript). 
However, possible justification for these expected results 
could be that the use of more antidiabetic medications 
(three or more agents) is accompanied with a lower dose 
of each component of the antidiabetic therapy, which 
consequently will decrease the probability of experi-
encing adverse events related to high dose of multiple 
therapy. However, this could not be confirmed without 
obtaining full data about the dose of antidiabetic therapy 
being used and also having an appropriate sample size.
the role of comorbidities and polypharmacy
The coexistence of other chronic diseases and the wide 
use of other chronic medications (polypharmacy) among 
our study cohort could be another independent risk 
factor that increased the risk of hypoglycaemia. The 
concurrent use of such chronic medications could be a 
time-varying confounder as they were not included in the 
analysis. The average BMI of our study cohort was 31.7 kg/
m2 (SD=6.2), which is classified as obese by WHO.21 This 
could be another risk factor in increasing the probability 
of patients’ experiencing hypoglycaemia.22 However, we 
expect that our estimate will not be affected by these base-
line variables because of the short observation windows in 
our study design.
In our study, a cohort of patients with DM, hyperten-
sion, dyslipidaemia and microalbuminuria were the most 
Table 3 Case-crossover results for the risk of hypoglycaemia due to the use of multiple antidiabetic medications therapy in 







(days) OR (95% CI)
Patients with hypoglycaemic 
events with any degree of 
severity
Primary 1–15 16–45 46–60 5.00 (1.10 to 22.82)
Model 1 1–30 31–60 61–90 9.00 (1.14 to 71.04)
Model2 1–15 16–22 23–37 5.00 (0.58 to 42.80)
Model 3 1–15 16–22 23–37, 38–52, 
53–67, 68–82
11.31 (2.39 to 53.57)
Patients with glucose 
measurement ≤70 mg/dL
Secondary 1–15 16–45 46–60 6.00 (0.72 to 49.84)
Model 1 1–30 31–60 61–90 5.00 (0.58 to 42.80)
Model 2 1–15 16–22 23–37 –
Model 3 1–15 16–22 23–37, 38–52, 
53–67, 68–82
17.40 (2.11 to 143.48)
Table 4 Case-crossover results for the risk of hypoglycaemia due to the use of multiple antidiabetic medications therapy 







(days) OR (95% CI)
Patients with 
hypoglycaemic events 
with any degree of 
severity
Primary 1–15 16–45 46–60 10.00 (1.28 to 78.12)
Model 1 1–30 31–60 61–90 9.00 (1.14 to 71.04)
Model 2 1–15 16–22 23–37 5.00 (0.58 to 42.80)
Model 3 1–15 16–22 23–37, 38–52, 
53–67, 68–82
13.04 (2.79 to 60.96)
Patients with glucose 
measurement ≤70 mg/dL
Secondary 1–15 16–45 46–60 6.00 (0.72 to 49.84)
Model 1 1–30 31–60 61–90 5.00 (0.58 to 42.80)
Model 2 1–15 16–22 23–37 –
Model 3 1–15 16–22 23–37, 38–52, 
53–67, 68–82
17.40 (2.11 to 143.48)
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commonly coexisted diseases having a prevalence rate of 
86.3%, 76.9% and 42.3%, respectively. Previous studies 
have established that comorbidities such as cardiovas-
cular diseases and chronic kidney diseases increase the 
risk of hypoglycaemic events.23 Likewise, the use of cardio-
vascular system medications (eg, aspirin, angiotensin 
receptor blocker, calcium channel clocker, beta-blocker 
and ACE inhibitors) was common across the study cohort 
and could have contributed to increasing the hypogly-
caemic risk.24 25
strengths and weaknesses
This study has several strengths. To our knowledge, this 
was the first pharmacoepidemiological study to investi-
gate the association between the use of multiple antidia-
betic medications therapy and the odds of hypoglycaemia. 
It is the first study in the Middle East on this topic, thus 
increasing the generalisability of current evidence beyond 
the Caucasian population. Unlike the classical cohort and 
case–control studies (between-subject comparison), the 
case-crossover study design itself (within-subject compar-
ison) offers the advantage of eliminating the effects of 
time-independent confounding variables such as patients’ 
demographics, genetic factors and family medical history 
that may not be commonly available. In addition, our 
study included hypoglycaemic events from different 
degrees of severity and was not restricted to severe cases 
that required hospitalisation, which increase the general-
isability of our findings. Unlike previous studies based on 
prescribing data,20 we used dispensing data, which elimi-
nated the primary non-compliance (ie, not obtaining the 
prescription), however, it does not guarantee full compli-
ance. Finally, our study did not restrict the comparison to 
a specific antidiabetic combination therapy and studied 
the exposure to any antidiabetic combination therapy.
Our study also has some limitations. The relatively 
small sample size of our study cohort has led to wide CIs. 
However, we used multiple control windows in the sensi-
tivity analyses to increase the statistical power. Patients 
could still have residual confounders that changed over 
a short period of time, such as the severity of the disease 
and exposure to specific high-risk medications, which 
could itself contribute to an increase in the odds of hypo-
glycaemia. However, our observation period was less than 
1 year and thus the effect of such a time trend is antic-
ipated to be low. We were not able to test the effect of 
the different doses of antidiabetic combination therapies 
used by the patients, which could have had a possible 
effect on hypoglycaemia. Finally, the vast majority of the 
patients in the study are covered by health insurance, so 
the results could be more representative to this popula-
tion of health-insured patients, which is reported in the 
literature to have a significant role on increasing patient’s 
access and use of healthcare resources and decrease their 
out-of-pocket spending.26
Although our study uses a different design and a 
completely different population, our results are very 
similar to previous published results,20 this serves as an 
external validation of our result that the use of multiple 
antidiabetic medications therapy increases the odds of 
hypoglycaemic events.
In conclusion, this study found that the use of multiple 
antidiabetic medications therapy was associated with an 
increased odd of hypoglycaemic events. Patients and 
healthcare professionals should be extra vigilant when 
patients are on multiple antidiabetic medications therapy, 
especially the combination of sulfonylurea and insulin.
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